Melinta Therapeutics Announces U.S. FDA Acceptance of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia
19 juin 2019 07h30 HE
|
Melinta Therapeutics
~ Application Seeks to Expand Label to Include an Indication and Phase III Data for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia (CABP) ~ ~ PDUFA Date Set for October...
Melinta Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
09 mai 2019 16h00 HE
|
Melinta Therapeutics
~ Revenue of $14.1 million, Including Net Product Sales of $11.8 million, for the First Quarter 2019 ~ ~ Reduction of Operating Expenses of 34 Percent, or $19.8 million, Year-Over-Year ~ ~...
Melinta Therapeutics Launches Antibiotic Baxdela™ (delafloxacin) in the United States
29 janv. 2018 07h00 HE
|
Melinta Therapeutics
– Approved for adult patients with acute bacterial skin and skin structure infections (ABSSSI) – – Provides coverage of gram-positive and gram-negative pathogens; only FDA-approved fluoroquinolone...
Melinta Therapeutics Enters Into Agreement to Acquire Infectious Disease Business from The Medicines Company
29 nov. 2017 07h00 HE
|
Melinta Therapeutics
- Acquisition positions Melinta as durable and focused pure-play antibiotics company with four marketed products: Baxdela®, Vabomere®, Orbactiv®, and Minocin IV® - - Peak sales potential of the...
Melinta Therapeutics Announces FDA Clearance of Antimicrobial Susceptibility Tests Concurrent with Baxdela Launch in the United States
30 oct. 2017 08h01 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing and commercializing novel antibiotics to treat serious bacterial infections, announced...
Melinta Therapeutics Publication Reinforces Baxdela Tolerability and Activity in Patients with MRSA Infections and Challenging Comorbidities
24 oct. 2017 08h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics Presents Outcomes of Baxdela Treatment of Gram-Positive and Gram-Negative Pathogens at IDWeek
04 oct. 2017 13h13 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., Oct. 04, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics Presenting Detailed Analyses from Baxdela Phase 3 ABSSSI Trials and In Vitro Performance against Isolates of Resistant CABP and other Infections
25 sept. 2017 08h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing and commercializing novel antibiotics to treat serious bacterial infections, announced...
Melinta Therapeutics Presentations at ECCMID Show Potential of Baxdela in Obese and other Challenging Patient Types
21 avr. 2017 09h37 HE
|
Melinta Therapeutics
New Haven, Conn, April 21, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced today that the...
Melinta Therapeutics Highlighting Activity of Baxdela as well as Progress on Macrolide and Pyrrolocytosine Candidates at ECCMID 2017
19 avr. 2017 14h42 HE
|
Melinta Therapeutics
New Haven, Conn, April 19, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced today that there will...